From startups to leading global companies, Greater Fort Lauderdale provides a stimulating and supportive business environment for success in the life sciences.

An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global…


AbbVie, Galapagos’ Kalydeco challenger clears phase 2

Galapagos, Gilead start phase 3 trial of filgotinib in Crohn’s

ProQR surges on CF data on busy day for the field

Galapagos CEO confirms Gilead standstill agreement is active, quashing takeover talk

Gilead, Galapagos start PhIII of RA drug, 8 months after AbbVie began rival program

EuroBiotech: More Articles of Note

Galapagos, Gilead include high dose in PhIII RA trial after talk with FDA

AbbVie adds $250M in milestones to Galapagos cystic fibrosis deal

EuroBiotech Report: Galapagos bolsters case for Gilead-partnered Crohn’s drug

Galapagos bolsters case for Gilead-partnered Crohn’s drug with 20-week data